Maxim Group Starts Armata Pharmaceuticals (ARMP) at Buy

Maxim Group analyst Jaosn McCarthy initiates coverage on Armata Pharmaceuticals (NYSE: ARMP) with a Buy rating and a price target of $8.00.

The analyst comments "Phage therapy is a re-emerging strategy with significant opportunities in infectious disease, including in combinations with standard of care antibiotics. As antibiotic resistance remains an ever-growing global health issue, there is demand for new therapies, and with its phage technology and pipeline, Armata is well-positioned for success."

For an analyst ratings summary and ratings history on Armata Pharmaceuticals click here. For more ratings news on Armata Pharmaceuticals click here.

Shares of Armata Pharmaceuticals closed at $3.71 yesterday.

You May Also Be Interested In

• Freedom Broker Starts Copart (CPRT) at Buy
• TD Cowen Assumes Constellation Brands (STZ) at Buy
• Deutsche Bank Upgrades Softbank Group Corp. (9984:JP) (SFTBY) to Buy